



A composite image featuring a hand reaching out from the left side towards a bright sun in the upper right corner. The sun has a prominent starburst effect. The background is a landscape with a blue sky, white clouds, and a foreground of dark, rocky terrain with some green vegetation. The overall scene suggests a sense of reaching towards light or creation.

# Scheppingsverhaal

A hand is shown reaching out from the left side of the frame towards the right. The background is a bright, clear blue sky with a sun in the upper right corner, creating a starburst effect. Below the sky, there is a dark, forested mountain range. The overall scene is bright and clear, suggesting a high-altitude or mountain environment.

# **Scheppingsverhaal Medisch Laboratorium**

A hand is shown in the upper left, reaching out towards the right. The background is a bright, clear blue sky with a large, multi-pointed sunburst in the upper right. Below the sky, there is a dark, forested mountain range. The overall scene is bright and clear, suggesting a sunny day in a mountainous area.

**Op de Eerste Dag**

A hand is shown reaching out from the left side of the frame towards a bright sun in the upper right corner. The sun is partially obscured by a lens flare effect. The background is a clear blue sky with some light clouds. In the lower portion of the image, there is a dark, rocky foreground with some green vegetation and a path leading into the distance.

Op de Eerste Dag  
Schiep Roche een IgX Bepaling

A hand is shown reaching out from the left side of the frame towards the center. The background is a bright, sunny sky with a lens flare effect from the sun in the upper right. Below the sky, there is a dark, forested mountain range. The overall scene is bright and clear.

**Op de Eerste Dag  
Schiep Roche een IgX Bepaling  
.....Referentiewaarden 6 – 14 g/L**

A hand is shown in the upper left, reaching out towards a bright sun in the upper right. The sun has a prominent starburst effect. The background is a clear blue sky with some light clouds. Below the sky, there is a dark green forest of evergreen trees. In the foreground, there is a dark, rocky or gravelly path leading towards the right.

**Op de Tweede Dag**

A hand is shown reaching out from the left side of the frame towards the center. The background is a bright, clear blue sky with a large, multi-pointed sunburst effect in the upper right corner. Below the sky, there is a dark, forested mountain range. The overall scene is bright and clear, suggesting a sunny day in a mountainous region.

Op de Tweede Dag  
Schiep Beckman een IgX Bepaling



A hand is shown reaching out from the left side of the frame towards a bright sun in the upper right. The sun is partially obscured by a lens flare effect. The background consists of a clear blue sky with some light clouds and a mountain range with green vegetation and rocky terrain in the foreground.

Op de Tweede Dag  
Schiep Beckman een IgX Bepaling  
.....Referentiewaarden 4 – 11 g/L

A hand is shown in the upper left, reaching out towards the right. The background is a bright, clear blue sky with a large, multi-pointed sunburst in the upper right. Below the sky, there is a dark, forested mountain range. The overall scene is bright and clear.

**Op de Derde Dag**

A hand is shown reaching out from the left side of the frame towards the right. The background is a bright, sunny sky with a prominent starburst effect from the sun in the upper right corner. Below the sky, there is a landscape of green hills and a path leading into the distance. The overall scene is bright and clear.

Op de Derde Dag  
Schiep Abbott een IgX Bepaling

A hand is shown reaching out from the left side of the frame towards the center. The background is a bright, sunny sky with a lens flare effect from the sun in the upper right. Below the sky, there is a mountain landscape with green vegetation and a path leading towards the distance.

**Op de Derde Dag  
Schiep Abbott een IgX Bepaling  
.....Referentiewaarden 8 – 20 g/L**

A hand is shown in the upper left, reaching out towards the right. The background is a bright, clear blue sky with a large, multi-pointed sunburst in the upper right. Below the sky, there is a dark, forested mountain range. The overall scene is bright and clear, suggesting a sunny day in a high-altitude or mountainous area.

**Op de Zevende Dag**

A hand is shown reaching out from the left side of the frame towards the center. The background is a bright, clear blue sky with a large, multi-pointed sunburst effect in the upper right corner. Below the sky, there is a dark, silhouetted mountain range with some green vegetation in the foreground. The overall scene is bright and clear.

Op de Zevende Dag  
Zag het Medisch Laboratorium

A hand is shown reaching out from the left side of the frame towards the center. The background is a bright, sunny sky with a lens flare effect from the sun in the upper right. Below the sky, there is a landscape with green hills and a path leading towards the distance.

Op de Zevende Dag  
Zag het Medisch Laboratorium  
Dat het niet goed was

A hand is shown in the upper left, reaching out towards a bright sun in the upper right. The sun has a prominent starburst effect. The background is a landscape with a blue sky, white clouds, and a dark, forested mountain range in the foreground.

**Want wat was het Probleem?**



# Eén IgX Bepaling

## Verschillende Referentie Waarden

Roche 6-14 g/L

Beckman 4 – 11 g/L

Abbott 8 – 20 g/L

## Verwarring

.....Elkaar tegensprekende Richtlijnen

.....Andere Beslisgrenzen

.....Gevaar Foute Beslissingen Patiënten

# Algemeen Probleem

1. Ontdekking Nieuw Analiet
2. Alle Fabrikanten willen erbij zijn
3. Ontwikkelen een eigen Test
4. Niet vergelijkbare resultaten
5. Verwarring

**Daar moet wat aan gedaan worden**

**En dat gebeurt ook.....**


**.....Op wereldschaal**

# Equivalence, Why?

“Results between different methods should be equivalent, within clinically meaningful limits, to enable optimum use of clinical guidelines for disease diagnosis and patient management”

# Traceability Chain

Definition of the Analyte




**Standardization**

Interpretation  
Patient Result

De

# Equivalence by Standardization?



## Frustration Pragmatic Americans:

- No Reference materials/methods
- Development takes so long
- Costs are so high

Interpretation  
Patient Result

# **Tweede Benadering**

## **Naspeurbaarheid Laboratorium Resultaat**

### **“Traceability”**

**Standaardisatie: Échte Waarheid**  
**Referentie Methode**  
**Absoluut IJkpunt**

# **Tweede Benadering**

## **Naspeurbaarheid Laboratorium Resultaat**

### **“Traceability”**


**Standaardisatie: Échte Waarheid**  
**Referentie Methode**  
**Absoluut IJkpunt**

**Harmonisatie: Relatieve Waarheid**  
**Arbitraire Referentie Methode**  
**Arbitrair IJkpunt**



# AACC Harmonization Initiative


*Perfect is the Enemy of Good*



Clinical Lab Test Harmonization

# You want something to happen

*The American Approach*




## Let's Start Doing It

# You want something to happen

*The American Approach*

**SKML** →



## Let's Start Doing It

# You want something to happen

*The American Approach*

**SKML** →

Conference  
*AACC Oct 2010*

Steering Committee  
*Jan. 2011 – Sept 2012*

Task Force 1  
*Organization Structure*

Task Force 2  
*Toolbox*

Task Force 3  
*Prioritization*

**Cas  
Weykamp** →


Permanent Organ.  
*September 2012*

CAP IFCC EFLM  
KSLM ACB  
AACB SBAC

## Let's Start Doing It


# You want something to happen

*The American Approach*




## Let's Start Doing It

# AN INFRASTRUCTURE FOR HARMONIZATION



# You want something to happen


*The American Approach*



## Let's Start Doing It


# You want something to happen

*The American Approach*



## Let's Start Doing It





# The Process of Harmonization

*How do you do it?*

## Mission Statement Task Force Toolbox:

***“Develop a Toolbox of.....  
.....Technical Procedures  
.....that can be used  
.....to achieve Harmonization  
.....for any Measurand”***

# **Harmonization is Technically Achievable**

**?**

# Harmonization is Technically Achievable

## Unit to express Degree of harmonization

*Intermethode CV*

### Degree of Harmonization

- Before harmonization
- After Harmonization
- Desired

### Example Troponine

-Intermethode CV before:	73%
-Intermethode CV after:	18%
-Intermethode CV desired:	10%

### Harmonization Technically Achievable?

*It is better but is an intermethod CV of 10% worth doing an effort?*

# **Toolbox**

**Create Tools that allow to gather**

**Essential Information....**

## Two Methods; same samples measured fivefold

<u>Method A</u>	<u>Method B</u>
100	100
26	101
144	103
87	102
68	100

Harmonization achievable?

## Two Methods; same samples measured fivefold

<u>Method A</u>	<u>Method B</u>
100	100
26	101
144	103
87	102
68	100

Harmonization achievable?

***No, Method A is not reproducible***

## Two Methods; 5 Patients measured

<u>Method A</u>	<u>Method B</u>
20	20
40	40
60	56
80	61
100	62

Harmonization Achievable?



## Two Methods; 5 Patients measured

<u>Method A</u>	<u>Method B</u>
20	20
40	40
60	56
80	61
100	62

Harmonization Achievable?

*Questionable; Method B not linear high levels*

## Two Methods; 5 patients measured

<u>Method A</u>	<u>Method B</u>
100	100
50	100
100	50
50	50
100	80

Harmonization Achievable?

## Two Methods; 5 patients measured

<u>Method A</u>	<u>Method B</u>
100	100
50	100
100	50
50	50
100	80

Harmonization Achievable?

*Mission impossible: Heterogeneity*

## Two methods; 5 patients measured

<u>Method A</u>	<u>Method B</u>
20	40
40	80
60	120
80	160
100	200

Harmonization achievable?

## Two methods; 5 patients measured

<u>Method A</u>	<u>Method B</u>
20	40
40	80
60	120
80	160
100	200

Harmonization achievable?

*Yes – Calibration – Simple Factor 2*


# Lessons Exercises

4 Properties of the methods determine  
If harmonization is achievable:

1. Reproducibility Methods (not)
2. Linearity Methods (not/complicated)
3. Heterogeneity reagents/epitopes (not)
4. Way of Calibration (yes)

*To estimate achievability of harmonization  
these parameters are to be assessed*

# Parameters to be Determined



**If properties of tests allow harmonization  
.....in principle**

**Two things are required to achieve harmonization  
.....in practice**

- Calibrators**
- Method Value Assignment**



One more Exercise

Candidate Calibrator assayed with 4 patient samples with method A and method B

Sample	Method A	Method B
Calibrator	60	60
Pat 1	20	40
Pat 2	40	80
Pat 3	60	120
Pat 4	80	160

Candidate Calibrator Suitable?

One more Exercise


Candidate Calibrator assayed with 4 patient samples with method A and method B

Sample	Method A	Method B
Calibrator	60	60
Pat 1	20	40
Pat 2	40	80
Pat 3	60	120
Pat 4	80	160


Candidate Calibrator Suitable?

***No, not commutable***


# Parameters of the Harmonization Tools



# Parameters to be Determined



# Parameters to be Determined



## Information Required

*To assess if harmonization  
Is technically achievable*

1. Reproducibility
2. Relationship
3. Heterogeneity
4. Calibration
5. Overview

6. Commutability
7. Stability
8. Sustainability
9. Value Assignment
10. Availability
11. Costs
12. Will to Harmonize

**13. Harmonization Achievable**

## Experimental Design IHP

*Samples included to get all information*

**Executed all relevant methods**

32 Samples  
of individual persons  
healthy and diseased  
assayed in triplicate

5 Mixtures  
of the samples of the  
individual persons

Linearity Panel  
of 5 samples made from  
the individual persons

3 Candidate Calibrators

2 Additional Batches  
of one Candidate Calibrator

2 Stored Vials  
of one Candidate Calibrator

# Information Required

*To assess if harmonization  
Is technically achievable*

1. Reproducibility
2. Relationship
3. Heterogeneity
4. Calibration
5. Overview

6. Commutability
7. Stability
8. Sustainability
9. Value Assignment
10. Availability
11. Costs
12. Will to Harmonize

13. Harmonization Achievable

# Experimental Design IHP

*Samples included to get all information*

32 Samples  
of individual persons  
healthy and diseased  
assayed in triplicate


5 Mixtures  
of the samples of the  
individual persons

Linearity Panel  
of 5 samples made from  
the individual persons

3 Candidate Calibrators

2 Additional Batches  
of one Candidate Calibrator

2 Stored Vials  
of one Candidate Calibrator



## **Conclusion**

Results of Protocol

Discloses all essential information


## **Next**

Do it and

Monitor Success



# Parameters to be Determined



# Parameters to be Determined

Process Harmonization




14. Effort


15. Success

# Effort and Success

*Included in the Toolbox of HIG*




# EQA organisers will play a vital role in The monitoring of Harmonization Efforts



Clinical Lab Test Harmonization

# AN INFRASTRUCTURE FOR HARMONIZATION



Mooie Gereedschapskist.....  
.....Luchtfietserij?

Mooie Gereedschapskist.....  
.....Luchtfietsrij?

Doet SKML iets?  
.....Heeft SKML iets gedaan?


Mooie Gereedschapskist.....  
.....Luchtfietsrij?

Doet SKML iets?  
.....Heeft SKML iets gedaan?

Inderdaad:  
Sectie HIM heeft wat gedaan!




# Pilot 1 to test AACCC Toolbox: Reuma



1. Protocol is executable
2. Harmonization impossible due to Heterogeneity
3. NIBSC suitable calibrator
4. No method to assign values to calibrators
5. Mixtures do not behave like single donations

# Pilot 2: a-CCP

## Parameters to be Determined



1. Protocol is executable
2. Current Equivalence 79% Achievable Equivalence 17%
3. NIBSC 1066 suitable calibrator/ one-point calibration
4. No method to assign a value to calibrator
5. Mixtures behave like single donations

Er was ook al wat gedaan

Harmonisatie aantal Eiwitten

IRMM: Referentie Preparaat CRM470

Er was ook al wat gedaan  
Harmonisatie aantal Eiwitten  
IRMM: Referentie Preparaat CRM470

Alle Fabrikanten Geconformeerd  
Dus resultaat alle labs zelfde?

Er was ook al wat gedaan  
Harmonisatie aantal Eiwitten  
IRMM: Referentie Preparaat CRM470

Alle Fabrikanten Geconformeerd  
Dus resultaat alle labs zelfde?

**Zou het?**

**Sectie HIM van de SKML:  
.....Dat gaan we testen**

- 120 ampullen CRM470 gekocht**
- Combi Immuno Chemie 2012.1A**

**Als alles klopt: Recovery 100%**

# CRM 470 ingezet als Rondzendmonster

Eiwit	n	Target in g/L Bijsluiter CRM470	Overall Gemiddelde Rondzendin 2012.1A (Interlab CV %)	Recovery
Albumine	69	37.2	37.3 (5%)	100%
Haptoglobine	99	0.889	0.916 (5%)	103%
IgA	97	1.80	1.79 (4%)	99%
IgG	111	9.17	8.84 (6%)	96%
IgM	99	0.723	0.736 (5%)	102%
Transferrine	110	2.36	2.42 (5%)	103%
AAT	56	1.12	1.15 (8%)	103%
Overall				101%

# Recovery CRM470 per Eiwit per Methode

Methode	Albumine	Haptoglo	IgA	IgG	IgM	Transferr	AAT	Overall
Overall	100	103	99	96	102	103	103	101
Abbott Architect	103	98	95	98	105	98	105	100
Beckman Image	100	98	100	99	100	103	111	102
Beckman UniCel	99	102	99	96	108	104	111	103
Siemens Behring	96	99	102	100	103	98	102	100
Siemens ProSpec	102	100	103	102	101	94	101	101
Siemens VISTA	100	100	93	94	93	96	-	96
Olympus	102	90	91	99	98	106	107	99
Roche Cobas 6000	98	108	100	92	102	104	97	100
Roche Integra	106	104	104	94	103	101	91	100
Roche Modular	103	103	100	97	101	104	101	101



**Elk jaar herhalen**

**.....Actueel Beeld Harmonisatie**

**Te duur (€120/ampul)**

**Alternatief:**

- Grote batch monsters gemaakt**
- Afgeijkt op CRM 470**
- Combi Immuno Chemie**

**2013 – 2014 – 2015 – 2016 - 2017**

**“Doorloper”**

# Afijken op CRM 470?

Pragmatisch

Door Deelnemers Combi Immuno chemie

“Doorloper” = 2012.1B

Veel laboratoria

Lage Meetonzekerheid

# IJken Rondzendmonster op CRM470

X = referentiewaarde rondzendmonster (doorloper)

Y = referentiewaarde CRM 470 zoals opgegeven  
in bijslutier IRMM (9.17g/L)

Z = gemiddelde alle laboratoria gemeten in CRM470  
(2012.1A) in de rondzending (8.84 g/L)

U = gemiddelde alle laboratoria gemeten in doorloper  
(2012.1B) in de rondzending (8.59 g/L)

$$X = 8.59 \times 9.17 / 8.84 = 8.91 \text{ g/L}$$

# IJken Rondzendmonster op CRM470

<b>Eiwit</b>	<b>Gemiddeld Gemeten In rondzending 2012.1B (Interlab CV)</b>	<b>IJkfactor Afgeleid uit CRM470</b>	<b>Referentiewaarde In de doorloper</b>
Albumine	35.5 (5%)	37.2/37.3	35.4
Haptoglobine	1.326 (4%)	0.889/0.916	1.287
IgA	2.05 (4%)	1.80/1.79	2.06
IgG	8.59 (6%)	9.17/8.84	8.91
IgM	0.824 (5%)	0.723/0.736	0.809
Transferrine	2.23 (4%)	2.36/2.42	2.175
AAT	1.32 (8%)	1.12/1.15	1.286

# Recovery in CRM470 en Rondzendmonster

Methode	Albumine		Haptoglob		IgA		IgG		IgM		transferrine		AAT		Overall	
	CRM 470	Dr lop	CRM 470	Dr lop	CRM 470	Dr lop	CRM 470	Dr lop	CRM 470	Dr lop	CRM 470	Dr lop	CRM 470	Dr lop	CRM 470	Dr lop
Overall	100	100	103	103	99	99	96	96	102	102	103	103	103	103	101	101
AbbArch	103	105	98	99	95	95	98	101	105	105	98	99	105	104	100	101
Bec Imm	100	98	98	98	100	101	99	101	100	103	103	107	111	113	102	103
Beck Un	99	99	102	101	99	98	96	97	108	101	104	103	111	110	103	101
Sie Behr	96	105	99	107	102	102	100	99	103	106	98	101	102	102	100	102
Sie ProS	102	99	100	101	103	104	102	100	101	102	94	98	101	99	101	100
Sie VIST	100	102	100	102	93	92	94	88	93	100	96	98	-	-	96	97
Olympus	102	102	90	93	91	92	99	94	98	95	106	102	107	101	99	97
Roc6000	98	97	108	106	100	99	92	91	102	100	104	102	97	96	100	99
RocInteg	106	108	104	101	104	103	94	95	103	102	101	98	91	93	100	100
Roc Mod	103	102	103	104	100	100	97	95	101	103	104	105	101	100	101	101

# Beklaagdenbankje

Categorie	n	Eiwit/Methode
Zalm Zalm (4+)	2	(AAT Beckman Immage) (AAT Beckman UniCel)
Zalm Geel (3+)	0	-
Geel Geel (2+)	2	(Albumine Roche (Integra) (Haptoglobine Roche Cobas 6000)
Geel Groen (1+)	6	-
Groen Groen (0)	67	-
LBlauw Groen (1-)	4	-
LBlauw LBlau (2-)	4	(IgA Siemens VISTA) (IgA Olympus) (IgG Roche C6000) (AAT Roche Integr)
DBlauw LBlau (3-)	2	(Haptoglobine Olympus) (IgG Siemens VISTA)
DBlauw DBLau (4-)	0	-

# Effect op Fabrikanten?

**Roche**

# Effect op Fabrikanten?

Graag willen wij u informeren over de her-standaardisatie van vier speciale eiwitten bepalingen namelijk de Tina-quant®  $\alpha$ -1 Antitrypsine, Haptoglobine, IgG gen. 2, Prealbumine en Albumine. Het nieuwe ERM DA470k/IFCC is als referentie materiaal hiervoor gebruikt.

Intern onderzoek naar aanleiding van klantenmeldingen, afwijkingen in de externe kwaliteitsbewakingssystemen en onderlinge vergelijkbaarheid tussen Roche systemen hebben geleid tot een nieuwe master lot kalibratie van Tina-quant®  $\alpha$ -1 Antitrypsine, Haptoglobine, IgG gen. 2, Prealbumine en Albumine bepalingen. Door deze master lot kalibratie wordt het huidige niveau van de C.f.a.s. PAC gejusteerd naar het referentiemateriaal ERM DA470k/IFCC.

De volgende aanpassing van de C.f.a.s. PAC zijn:

+

Bepaling	INTEGRA	Modular P	c501/c502	c701/c702
$\alpha$ -1 Antitrypsine	-12.4%	-5.1%	-12.7%	-12.7%
Haptoglobine	-3.8%	-6.9%	-7.6%	-7.6%
IgG Gen.2	None	+4.1%	+11.5%	+4.1%
Prealbumine	-9.6%	None	-6.4%	-6.4%
Albumine	+4.5%	+4.5%	+4.5%	+4.5%



De consequentie voor deze referentie standaardisatie tegen ERM DA470k/IFCC referentie materiaal is

# Roche



# Er is nog wel wat te doen Ceruleplasmine

Methode	n	CRM470		Doorloper	
		Gemidd	SD	Gemidd	SD
Overall	29	0.169	0.017	0.274	0.036
Beckman Immage	9	0.187	0.015	0.316	0.024
Siemens Behring	5	0.164	0.009	0.266	0.009
Siemens Pro Spec	7	0.163	0.010	0.258	0.015
Olympus	1	0.170	-	0.260	-
Roche Cobas 6000	2	0.160	0.007	0.240	0.007
Roche Integra	1	0.140	-	0.260	-
Roche Modular	4	0.160	0.018	0.252	0.025

# Samenvatting

1. Optimale Zorg Patienten:  
Verschillende Methoden – Dezelfde Resultaten
2. Standaardisatie – Harmonisatie
3. SKML: Theorie op wereldschaal
4. SKML: Praktijk in Nederland  
Initiërend: Reuma – aCCP  
Controlerend: Eiwitten – Combi – CRM 470
5. Werkt: Fabrikanten sturen bij
6. Einddoel: harmonisatie = optimale zorg

A hand is shown in the upper left, reaching out towards a bright sun in the upper right. The sun has a prominent starburst effect. The background is a clear blue sky with some light clouds. Below the sky, there is a dark green forest of evergreen trees. In the foreground, there is a rocky, greyish-brown ground.

**Dank voor uw Aandacht**